BioClin Therapeutics, Inc., a San Ramon, California-based clinical stage drug development company, closed a $30m Series B financing.
The round was led by new investors Sofinnova Ventures and Ysios Capital, with participation from existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. In conjunction with the financing, Cory Freedland, PhD, of Sofinnova Ventures and Joël Jean-Mairet, PhD, of Ysios Capital have joined the Board of Directors. David Lacey, MD, has been named as a Board Observer.
The company, which has raised a total of $59m, intends to use the funds to advance its lead development candidate, B-701, for the treatment of patients with metastatic bladder cancer, or metastatic urothelial carcinoma (mUC), who have relapsed or are refractory to platinum therapy.
Led by Stephen Lau, CEO, BioClin Therapeutics is advancing B-701, a potential human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3), which is currently being evaluated in the treatment of metastatic bladder cancer.
The first clinical study is a Phase 1b/2 study of B-701 in combination with docetaxel.